NCT00574223

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

Double-Blind, Placebo-Controlled Study to Investigate Safety, Tolerability, Immunogenicity and Clinical Efficacy of a Specific Immunotherapy Combining Allergen With CYT003-QbG10 (CYT005-AllQbG10) in Adult Patients With Perennial Allergic Rhinoconjunctivitis Due to House Dust Mite Allergy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Cytos Biotechnology AG · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind placebo-controlled setting

Conditions

• Perennial Allergic Rhinoconjunctivitis
• House Dust Mite Allergy

Interventions

Type	Name	Description
DRUG	CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)	subcutaneous injections at 8 visits
DRUG	House dust mite allergen extract in combination with CYT003-QbG10-placebo	subcutaneous injections at 8 visits

Timeline

• Start date: 2007-11-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2007-12-17
• Last updated: 2009-04-27

Locations

1 site across 1 country: Switzerland